Key result
Estradiol valerate therapy lowers LDL ~22% and raises HDL ~21% in post-menopausal women.
Replacement therapy with estradiol valerate in 29 post-menopausal women reduced low-density lipoprotein (LDL) cholesterol concentrations by 22% and increased high-density lipoprotein (HDL) cholesterol by 21% after 12 months. Apart from a 67% increase of HDL-triglyceride estradiol had only a slight effect on the levels of lipoprotein triglycerides. Post-heparin plasma lipoprotein lipase (LPL) activity was significantly decreased in subjects with normal pre-treatment very-low-density lipoprotein (VLDL) triglyceride levels, and hepatic lipase (HL) activity was significantly decreased in the group as a whole. It is suggested that estradiol replacement therapy should be considered in climacteric women with high LDL-cholesterol or low HDL-cholesterol levels, or both.
No takes yet. Share an insight, caveat, or question.
Tikkanen et al. (1979) studied Post-menopausal hypercholesterolemia (n=29). Estradiol valerate was evaluated on Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol concentrations (22% reduction in LDL, 21% increase in HDL). Estradiol valerate replacement therapy in post-menopausal women reduced LDL cholesterol by 22% and increased HDL cholesterol by 21% after 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: